Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

ABSTRACT: Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic MSS CRC who have exposure to 2 or more lines of chemotherapy, to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab.

DISEASE(S): Colon Cancer,Colorectal Cancer,Colorectal Neoplasms,Pancreatic Cancer,Pancreatic Neoplasms

PROVIDER: 2318393 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR